Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EBV-specific TCR-T cells (Fudan University)
- Development stage
- Unknown
- Lead developer
- Fudan University
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
EBV-specific TCR-T cells (Fudan University) is an investigational adoptive cell therapy consisting of autologous T cells engineered to express T-cell receptors (TCRs) specific for Epstein-Barr Virus (EBV) antigens. Developed by Fudan University, this therapy is designed to treat recurrent or refractory EBV-positive nasopharyngeal carcinoma (NPC). The engineered T cells are programmed to recognize EBV-derived peptides presented by human leukocyte antigen (HLA) molecules on the surface of malignant cells. Upon recognition, the TCR-T cells undergo activation and expansion, leading to the targeted destruction of the tumor cells through cytotoxic mechanisms. The therapy is currently being evaluated in early-phase clinical trials to assess its safety, tolerability, and preliminary anti-tumor activity in patients who have failed standard-of-care treatments.
- Other names
- TCR-Fudan University-nasopharyngeal carcinomaEBV-specific TCR-T cellsEBV TCR-T-cell
02
Targets
EBNA1 (Epstein-Barr virus latency proteins)
Beyond the preview
Go deeper on EBV-specific TCR-T cells (Fudan University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EBV-specific TCR-T cells (Fudan University).